These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
762 related items for PubMed ID: 23461430
1. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Robinson JG. J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430 [Abstract] [Full Text] [Related]
2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A, Watts GF. Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [Abstract] [Full Text] [Related]
4. Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Ison HE, Clarke SL, Knowles JW. ; 1993 Aug. PubMed ID: 24404629 [Abstract] [Full Text] [Related]
5. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Polychronopoulos G, Tziomalos K. Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604 [Abstract] [Full Text] [Related]
6. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E, Salvetti M. High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [Abstract] [Full Text] [Related]
7. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. Patel RS, Scopelliti EM, Savelloni J. Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558 [Abstract] [Full Text] [Related]
8. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. Dixon DL, Sisson EM, Butler M, Higbea A, Muoio B, Turner B. J Cardiovasc Nurs; 2014 Dec; 29(5):E7-E12. PubMed ID: 24231894 [Abstract] [Full Text] [Related]
9. Low-density lipoprotein apheresis: an evidence-based analysis. Medical Advisory Secretariat. Ont Health Technol Assess Ser; 2007 Dec; 7(5):1-101. PubMed ID: 23074505 [Abstract] [Full Text] [Related]
10. 2017 Taiwan lipid guidelines for high risk patients. Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI, Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients. J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [Abstract] [Full Text] [Related]
11. Familial Hypercholesterolemia: Global Burden and Approaches. Tokgozoglu L, Kayikcioglu M. Curr Cardiol Rep; 2021 Sep 04; 23(10):151. PubMed ID: 34480646 [Abstract] [Full Text] [Related]
12. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Ito MK, Watts GF. Drugs; 2015 Oct 04; 75(15):1715-24. PubMed ID: 26370207 [Abstract] [Full Text] [Related]
13. My Approach to the Patient With Familial Hypercholesterolemia. Safarova MS, Kullo IJ. Mayo Clin Proc; 2016 Jun 04; 91(6):770-86. PubMed ID: 27261867 [Abstract] [Full Text] [Related]
14. Familial hypercholesterolemia treatments: Guidelines and new therapies. Raal FJ, Hovingh GK, Catapano AL. Atherosclerosis; 2018 Oct 04; 277():483-492. PubMed ID: 30270089 [Abstract] [Full Text] [Related]
15. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. J Clin Lipidol; 2018 Oct 04; 12(4):958-965. PubMed ID: 29685591 [Abstract] [Full Text] [Related]
16. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K. JAMA; 2016 Aug 16; 316(7):743-53. PubMed ID: 27533159 [Abstract] [Full Text] [Related]
17. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Yamashita S, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Daida H, Koga N, Oikawa S. J Atheroscler Thromb; 2022 May 01; 29(5):608-638. PubMed ID: 33980760 [Abstract] [Full Text] [Related]
18. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Stefanutti C, Morozzi C, Di Giacomo S. Curr Med Chem; 2012 May 01; 19(28):4861-8. PubMed ID: 22963620 [Abstract] [Full Text] [Related]
19. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ, European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Eur Heart J; 2014 Aug 21; 35(32):2146-57. PubMed ID: 25053660 [Abstract] [Full Text] [Related]
20. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment]. Češka R, Štulc T, Votavová L, Schwarzová L, Vaclová M, Freiberger T. Vnitr Lek; 2016 Aug 21; 62(11):887-894. PubMed ID: 28128575 [Abstract] [Full Text] [Related] Page: [Next] [New Search]